Pan-cancer investigation identifies ARL4A as a prospective therapeutic indicator for thyroid cancer
Abstract Background: ADP-ribosylation factor-like 4 A (ARL4A), a small GTPase involved in cytoskeletal dynamics and signal transduction, exhibits dysregulated expression in various cancers, yet its comprehensive role across tumor types, particularly in thyroid carcinoma (THCA), remains underexplored. This study aimed to perform a systematic pan-cancer analysis of ARL4A to elucidate its expression patterns, prognostic implications, genetic and epigenetic alterations, immune correlations, drug sensitivity, and functional contributions to THCA progression. Methods: Leveraging multi-omics data from TCGA and tools including TIMER2.0, GEPIA2,
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join â it's freeAlready a member? Log in